News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard May 26, 2023 COVID-19 Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU Download May 12, 2023 COVID-19 Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore Download May 9, 2023 Corporate and finance Novavax Reports First Quarter 2023 Financial Results and Operational Highlights Download May 9, 2023 COVID-19Seasonal influenza Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses Download May 4, 2023 Novavax to Participate in the BofA Securities 2023 Health Care Conference Download May 2, 2023 Corporate and finance Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023 Download Apr 27, 2023 Statement PREVENT-19 Adolescent Data Published in the Journal of the American Medical Association Network Open Download Apr 17, 2023 Statement Novavax’s Novel Matrix-M™ Adjuvant Technology is Key Component of Oxford Malaria Vaccine Download Apr 4, 2023 COVID-19Seasonal influenza Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases Download Mar 6, 2023 Novavax to Participate in TD Cowen's 43rd Annual Health Care Conference Download Mar 2, 2023 Corporate and finance Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) Download Feb 28, 2023 Corporate and finance Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Download Feb 21, 2023 Corporate and finance Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023 Download Feb 13, 2023 COVID-19 U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine Download Jan 27, 2023 StatementCOVID-19 Novavax Announces Plan to Deliver Updated Protein-based Vaccine Consistent with FDA Recommendations for 2023/2024 Vaccination Season at VRBPAC Meeting Download Jan 25, 2023 Corporate and finance Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) Download Jan 18, 2023 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster Download Jan 9, 2023 Corporate and finance Novavax Names John C. Jacobs as New President & Chief Executive Officer Download Jan 9, 2023 Statement Novavax to Participate in the 41st Annual J.P. Morgan Healthcare Conference Download Jan 5, 2023 Spanish, Italian and French Health Authorities Expand Recommendations for Use of Novavax COVID-19 Vaccine Download Dec 30, 2022 COVID-19Seasonal influenza Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Download Dec 28, 2022 Corporate and finance Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock Download Dec 16, 2022 StatementGlobal healthCOVID-19 German Health Authority Expands Recommendation for Use of Novavax COVID-19 Vaccine as a Booster Download Dec 15, 2022 Corporate and finance Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes Download Dec 15, 2022 Corporate and finance Novavax Announces Pricing of $65 Million Public Offering of Common Stock Download Dec 14, 2022 Corporate and finance Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes Download Dec 14, 2022 Corporate and finance Novavax Announces Proposed $125 Million Public Offering of Common Stock Download Dec 12, 2022 Statement Swiss and French Health Authorities Expand Recommendations for Use of Nuvaxovid COVID-19 Vaccine as a Booster Download Dec 7, 2022 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents Download Dec 2, 2022 Corporate and finance Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference Download Nov 29, 2022 COVID-19 World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults Download Nov 23, 2022 StatementCOVID-19 Termination of COVID-19 Vaccine Purchase Agreement with Gavi Download Nov 18, 2022 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults Download Nov 14, 2022 Corporate and finance Novavax to Participate in Jefferies London Healthcare Conference Download Nov 9, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults Download Nov 8, 2022 Corporate and finance Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights Download Nov 8, 2022 COVID-19 Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster Download Nov 1, 2022 Corporate and finance Novavax Appoints Rick Rodgers to Board of Directors Download Nov 1, 2022 Corporate and finance Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022 Download Oct 20, 2022 COVID-19Seasonal influenza Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022 Download Oct 19, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Download Oct 19, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults Download Oct 13, 2022 COVID-19Seasonal influenza Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains Download Oct 12, 2022 COVID-19 Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants Download Oct 10, 2022 Stanley Erck Opening Statement European Parliament – COVI Committee Hearing Delivered: October 10, 2022 Download Oct 10, 2022 COVID-19Seasonal influenza Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022 Download Oct 10, 2022 Statement Novavax and SK bioscience File a Post Approval Change Application in South Korea for Nuvaxovid™ COVID-19 Vaccine as a Booster in Adults Aged 18 and Older Download Oct 10, 2022 Statement Switzerland’s Federal Office of Public Health Recommends Novavax Nuvaxovid™ COVID-19 Vaccine as a Booster in Adults Aged 18 and Older Download Sep 27, 2022 COVID-19 Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom Download Sep 16, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17 Download Sep 16, 2022 Statement Novavax Requests Updated Emergency Use Listing from World Health Organization for Nuvaxovid™ COVID-19 Vaccine as a Booster in Adults Aged 18 and Older Download Sep 16, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older Download Sep 13, 2022 COVID-19 Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older Download Sep 12, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older Download Sep 7, 2022 Corporate and finance Novavax to Participate in Upcoming September Conferences Download Sep 2, 2022 COVID-19 Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older Download Sep 2, 2022 StatementCOVID-19 World Health Organization Approves SK bioscience as a Supplier of Novavax Nuvaxovid™ COVID-19 Vaccine Download Sep 1, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older Download Aug 26, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17 Download Aug 22, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Expands Recommendation for Novavax COVID-19 Vaccine, Adjuvanted to Adolescents Aged 12 Through 17 Download Aug 19, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17 Download Aug 18, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17 Download Aug 17, 2022 Novavax' COVID-19 Vaccine Recognized in U.S. Government Delegation Visit to Serum Institute of India Download Aug 17, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults Download Aug 15, 2022 Novavax Files in Taiwan for Expanded Emergency Use Authorization of Nuvaxovid™ COVID-19 Vaccine in Adolescents Aged 12 Through 17 Download Aug 15, 2022 COVID-19 Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older Download Aug 12, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17 Download Aug 11, 2022 Corporate and finance Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum Download Aug 10, 2022 StatementCOVID-19 Novavax and Serum Institute of India Receive Expanded Emergency Use Authorization for Novavax’ COVID-19 Vaccine in Thailand in Adolescents Aged 12 Through 17 Download Aug 8, 2022 Corporate and finance Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights Download Aug 8, 2022 StatementCorporate and finance Novavax Statement on Second Quarter 2022 Financial Results and Operational Highlights Download Aug 4, 2022 COVID-19 Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years Download Aug 1, 2022 StatementCOVID-19 Novavax Statement on U.S. Vaccinations with the Novavax COVID-19 Vaccine, Adjuvanted Underway Download Aug 1, 2022 Corporate and finance Novavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022 Download Jul 29, 2022 Novavax Requests Expanded Emergency Use Listing with World Health Organization for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 Download Jul 28, 2022 StatementCorporate and finance Novavax CEO Appointed to U.S.-India CEO Forum Download Jul 26, 2022 COVID-19 Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan Download Jul 26, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17 Download Jul 22, 2022 StatementCOVID-19 Novavax Statement on U.S. Availability of the Novavax COVID-19 Vaccine, Adjuvanted Download Jul 19, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Endorses Advisory Committee on Immunization Practices’ Recommendation for Novavax COVID-19 Vaccine, Adjuvanted Download Jul 19, 2022 COVID-19 U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older Download Jul 19, 2022 COVID-19 Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes Download Jul 15, 2022 StatementCOVID-19 Novavax COVID-19 Vaccine to be Reviewed at U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices Meeting on July 19, 2022 Download Jul 14, 2022 StatementCOVID-19 Novavax Statement on European Medicines Agency Nuvaxovid™ Label Update Related to Allergic Reaction Download Jul 13, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over Download Jul 11, 2022 COVID-19 U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine Download Jul 7, 2022 StatementGlobal healthCOVID-19 Novavax Files in Switzerland for Expanded Conditional Marketing Authorization of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Individuals Aged 18 and Over Download Jul 7, 2022 StatementGlobal healthCOVID-19 European Medicines Agency Approves SK bioscience as a Supplier of Novavax Nuvaxovid™ COVID-19 Vaccine Download Jul 5, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17 Download Jul 1, 2022 StatementGlobal healthCOVID-19 Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA Download Jun 28, 2022 COVID-19 Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants Download Jun 28, 2022 StatementGlobal healthCOVID-19 Novavax to Participate in Vaccines and Related Biological Products Advisory Committee Review of COVID-19 Vaccines Strain Composition Download Jun 23, 2022 COVID-19 Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over Download Jun 23, 2022 COVID-19 Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17 Download Jun 23, 2022 StatementGlobal healthCOVID-19 Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 Download Jun 17, 2022 StatementCOVID-19Seasonal influenza Novavax to Showcase Innovative Vaccine Data at Communicable Diseases & Immunisation Conference 2022 Download Jun 13, 2022 COVID-19 Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over Download Jun 7, 2022 COVID-19 FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older Download Jun 7, 2022 Corporate and financeCOVID-19 Novavax Statement on Stock Trading Halt; FDA Advisory Committee to Review Novavax’ COVID-19 Vaccine Download Jun 3, 2022 StatementCOVID-19 Novavax Statement on US FDA Briefing Document Related to Myocarditis/Pericarditis Download Show 5102550100 per page«12345»